Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 10/20 | 0.70 |
| ▸ | CA9 | Q16790 | 10/20 | 0.70 |
| ▸ | CA12 | O43570 | 9/20 | 0.70 |
| ▸ | CA7 | P43166 | 3/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | CA1 | P00915 | 4/20 | 0.62 |
| ▸ | CA3 | P07451 | 1/20 | 0.62 |
| ▸ | CA4 | P22748 | 1/20 | 0.62 |
| ▸ | CA6 | P23280 | 1/20 | 0.62 |
| ▸ | CA5A | P35218 | 1/20 | 0.62 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.62 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.62 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.62 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.62 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10706744 | 1.00 | CA2 (0.70) | CA2CA9CA12CA7POLB | |
| Azobenzene SCHEMBL28217411 | 0.90 | CA2 (0.81) | CA2CA9CA12CA7POLB | |
| SCHEMBL28217410 | 0.89 | CA2 (0.65) | CA2CA9CA12CA7POLB | |
| Azobenzene SCHEMBL5573397 | 0.84 | ALDH1A1 (0.67) | CA2CA9CA12CA7POLB | |
| SCHEMBL10867845 | 0.83 | CA2 (1.00) | CA2CA9CA12CA7POLB | |
| SCHEMBL11445876 | 0.83 | CA2 (1.00) | CA2CA9CA12CA7POLB | |
| SCHEMBL27094281 | 0.82 | POLB (0.69) | CA2CA9CA12CA7POLB | |
| SCHEMBL31060725 | 0.81 | CA2 (1.00) | CA2CA9CA12CA7POLB | |
| SCHEMBL29164152 | 0.80 | CA2 (0.78) | CA2CA9CA12CA7POLB | |
| Azobenzene SCHEMBL29181662 | 0.79 | POLB (0.65) | CA2CA9CA12CA7POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115647-B2 | Method of inhibiting neoplastic cells with indole derivatives | OSI PHARMACEUTICALS, INC. (US) | 2006-10-03 | — | — | US | disclosed |
| US-20020143022-A1 | Method of inhibiting neoplastic cells with indole derivatives | OSI PHARMACEUTICALS, INC. | 2002-10-03 | — | — | US | disclosed |
| US-6410584-B1 | ANTICANCER AGENTS | CELL PATHWAYS, INC. | 2002-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143022-A1 | Method of inhibiting neoplastic cells with indole derivatives | IDO1, IDO2, INMT | CA2 1694/4885CA9 1814/4885CA12 2258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.